BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8678124)

  • 1. Relationship between T2-weighted hyperintensities (unidentified bright objects) and lower IQs in children with neurofibromatosis-1.
    Denckla MB; Hofman K; Mazzocco MM; Melhem E; Reiss AL; Bryan RN; Harris EL; Lee J; Cox CS; Schuerholz LJ
    Am J Med Genet; 1996 Feb; 67(1):98-102. PubMed ID: 8678124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thalamo-striatal T2-weighted hyperintensities (unidentified bright objects) correlate with cognitive impairments in neurofibromatosis type 1 during childhood.
    Chabernaud C; Sirinelli D; Barbier C; Cottier JP; Sembely C; Giraudeau B; Deseille-Turlotte G; Lorette G; Barthez MA; Castelnau P
    Dev Neuropsychol; 2009; 34(6):736-48. PubMed ID: 20183730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain morphometry, T2-weighted hyperintensities, and IQ in children with neurofibromatosis type 1.
    Greenwood RS; Tupler LA; Whitt JK; Buu A; Dombeck CB; Harp AG; Payne ME; Eastwood JD; Krishnan KR; MacFall JR
    Arch Neurol; 2005 Dec; 62(12):1904-8. PubMed ID: 16344348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurofibromatosis type 1: diffusion weighted imaging findings of brain.
    Alkan A; Sigirci A; Kutlu R; Ozcan H; Erdem G; Aslan M; Ates O; Yakinci C; Egri M
    Eur J Radiol; 2005 Nov; 56(2):229-34. PubMed ID: 15963674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropsychological profile in Italian children with neurofibromatosis type 1 (NF1) and their relationships with neuroradiological data: Preliminary results.
    Parmeggiani A; Boiani F; Capponi S; Duca M; Angotti M; Pignataro V; Sacrato L; Spinardi L; Vara G; Maltoni L; Cecconi I; Pastore Trossello M; Franzoni E
    Eur J Paediatr Neurol; 2018 Sep; 22(5):822-830. PubMed ID: 29802023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unidentified bright objects in neurofibromatosis type 1: conventional MRI in the follow-up and correlation of microstructural lesions on diffusion tensor images.
    Ferraz-Filho JR; José da Rocha A; Muniz MP; Souza AS; Goloni-Bertollo EM; Pavarino-Bertelli EC
    Eur J Paediatr Neurol; 2012 Jan; 16(1):42-7. PubMed ID: 22088602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofibromatosis type 1: the cognitive phenotype.
    Hofman KJ; Harris EL; Bryan RN; Denckla MB
    J Pediatr; 1994 Apr; 124(4):S1-8. PubMed ID: 8151460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'Moya' than meets the eye: neurofibromatosis type 1 associated with Moyamoya syndrome.
    Tan RM; Chng SM; Seow WT; Wong J; Lim CC
    Singapore Med J; 2008 Apr; 49(4):e107-9. PubMed ID: 18418511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T2-weighted hyperintensities (unidentified bright objects) in children with neurofibromatosis 1: their impact on cognitive function.
    Goh WH; Khong PL; Leung CS; Wong VC
    J Child Neurol; 2004 Nov; 19(11):853-8. PubMed ID: 15658789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of cognitive functioning, whole brain volumes, and T2-weighted hyperintensities in neurofibromatosis-1.
    Cutting LE; Koth CW; Burnette CP; Abrams MT; Kaufmann WE; Denckla MB
    J Child Neurol; 2000 Mar; 15(3):157-60. PubMed ID: 10757470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of unidentified bright objects in the neurocognitive profile of neurofibromatosis type 1 children: a volumetric MRI analysis.
    Di Stasi M; Cocozza S; Buccino S; Paolella C; Di Napoli L; D'Amico A; Melis D; Ugga L; Villano G; Ruocco M; Scala I; Brunetti A; Elefante A
    Acta Neurol Belg; 2024 Feb; 124(1):223-230. PubMed ID: 37733157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterizing the microstructural basis of "unidentified bright objects" in neurofibromatosis type 1: A combined in vivo multicomponent T2 relaxation and multi-shell diffusion MRI analysis.
    Billiet T; Mädler B; D'Arco F; Peeters R; Deprez S; Plasschaert E; Leemans A; Zhang H; den Bergh BV; Vandenbulcke M; Legius E; Sunaert S; Emsell L
    Neuroimage Clin; 2014; 4():649-58. PubMed ID: 24936416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of "unidentified bright objects" on MRI for diagnosis of neurofibromatosis 1 in children.
    DeBella K; Poskitt K; Szudek J; Friedman JM
    Neurology; 2000 Apr; 54(8):1646-51. PubMed ID: 10762507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal evolution of unidentified bright objects in children with neurofibromatosis-1.
    Kraut MA; Gerring JP; Cooper KL; Thompson RE; Denckla MB; Kaufmann WE
    Am J Med Genet A; 2004 Aug; 129A(2):113-9. PubMed ID: 15316979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diffuse pontine lesions in children with neurofibromatosis type 1: making a case for unidentified bright objects.
    Hervey-Jumper SL; Singla N; Gebarski SS; Robertson P; Maher CO
    Pediatr Neurosurg; 2013; 49(1):55-9. PubMed ID: 24192157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using a semi-automated approach to quantify Unidentified Bright Objects in Neurofibromatosis type 1 and linkages to cognitive and academic outcomes.
    Harriott EM; Nguyen TQ; Landman BA; Barquero LA; Cutting LE
    Magn Reson Imaging; 2023 May; 98():17-25. PubMed ID: 36608909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalamic involvement in neurofibromatosis type 1: evaluation with proton magnetic resonance spectroscopic imaging.
    Wang PY; Kaufmann WE; Koth CW; Denckla MB; Barker PB
    Ann Neurol; 2000 Apr; 47(4):477-84. PubMed ID: 10762159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropsychological function and MRI abnormalities in neurofibromatosis type 1.
    Joy P; Roberts C; North K; de Silva M
    Dev Med Child Neurol; 1995 Oct; 37(10):906-14. PubMed ID: 7493724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examining the frontal subcortical brain vulnerability hypothesis in children with neurofibromatosis type 1: Are T2-weighted hyperintensities related to executive dysfunction?
    Roy A; Barbarot S; Charbonnier V; Gayet-Delacroix M; Stalder JF; Roulin JL; Le Gall D
    Neuropsychology; 2015 May; 29(3):473-84. PubMed ID: 25365565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the detectability of UBOs in Neurofibromatosis Type I patients with proton density-weighted and FLAIR sequences in 3T MRI.
    Tritt S; Hillenbrand N; Liesirova K; Moein G; Kieslich M; Porto L
    Eur J Paediatr Neurol; 2018 Jul; 22(4):615-619. PubMed ID: 29610060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.